Home
Markets
Charts & Ideas
Algo
News
Store
Brokers
Download
Economic Calendar
Trading Signals
WebTerminal
Heatmap
Type
/
to search: @user, $symbol
Search
Log in
Create an account
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
IMCR
#2126
Immunocore Holdings plc American Depositary Shares
32.000
0
USD
+0.98%
Sector:
Healthcare
Base:
USD
Profit Currency:
USD
Daily Range
Year Range
Daily Change
+0.98%
Monthly Change
+5.40%
6 month change
-4.42%
Year Change
-4.42%
Previous Close
31.690
0
Open
31.710
0
Bid
Ask
Low
31.710
0
High
32.190
0
Volume
9
Markets
US Stock Market
Healthcare
IMCR
Open full chart
Financials
Overview
Statement
Statistics
Quarterly
Annual
Income statement
Balance sheet
Cash flow
Value
2020
2021
2022
2023
2024
2025
Total assets
—
—
—
597 M
1.01 B
1.07 B
Total liabilities
—
—
—
228.16 M
648.79 M
686.24 M
Total equity
—
—
—
368.84 M
360.72 M
381.03 M
Total liabilities & shareholders' equities
—
—
—
597 M
1.01 B
1.07 B
Total debt
—
—
—
48.01 M
391.01 M
393.13 M
Net debt
—
—
—
-394.62 M
-429.36 M
-471.03 M
Immunocore Holdings plc - American Depositary Shares
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
News
Ideaya Biosciences Surges On Promising Results For Hard-To-Treat Melanoma
Jefferies downgrades Immunocore stock rating on revenue concerns
Immunocore at Leerink Conference: Strategic Growth and Innovation
Immunocore Holdings plc 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:IMCR) 2026-02-25
Immunocore Holdings plc (IMCR) Q4 2025 Earnings Call Transcript
Immunocore Holdings earnings missed by $0.40, revenue fell short of estimates
JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
Immunocore earnings ahead as melanoma pipeline advances
Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down